Vedolizumab and new‐onset spondyloarthritis: debunking the myth

Roseira, Joana; Marafini, Irene; Noor, Nurulamin M.

http://hdl.handle.net/10400.1/26338

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Vedolizumab and new‐onset spondyloarthritis Debunking the myth.pdf		131.33 KB	Adobe PDF	Download

Send Feedback

Authors

Roseira, Joana

Marafini, Irene

Noor, Nurulamin M.

Abstract(s)

Despite an increased understanding of the etiopathogenesis of Inflammatory Bowel Disease (IBD), prevention or cure remains a distant aspiration and current treatment approaches often do not achieve long‐term disease remission. An additional complexity is that IBD can also be associated with a range of extra‐intestinal manifestations (EIMs). Among these EIMs, peripheral and axial rheumatological manifestations are perhaps the most prevalent, grouped under the term spondyloarthritis (SpA). The presentation of SpA can be before or after IBD diagnosis and presents several unique challenges. Notably, the presence of SpA can significantly impact on quality of life for patients and influence therapeutic decision‐making.